^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    clofarabine

    i
    Other names: JC0707, Cl-F-ara-A, CAFdA, GZ-393590, SAR-393590
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    12d
    Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (clinicaltrials.gov)
    P2, N=31, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement
    |
    clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
    2ms
    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026
    Trial completion date
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    sirolimus • clofarabine • melphalan
    3ms
    AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)
    P3, N=5949, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    5ms
    VyClo: Vyxeos® With Clofarabine for Pediatric AML (clinicaltrials.gov)
    P1, N=25, Recruiting, Princess Maxima Center for Pediatric Oncology
    New P1 trial
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • clofarabine
    5ms
    Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 23 | Trial completion date: Apr 2027 --> Jul 2026 | Trial primary completion date: Oct 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)
    5ms
    NCI-2018-01198: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (clinicaltrials.gov)
    P2, N=42, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    6ms
    Discovery of a novel non-toxic analog of clofarabine for the treatment of triple negative breast cancer. (PubMed, Bioorg Med Chem Lett)
    Our preliminary structure-activity relationship study resulted in the identification of analog 9 with enhanced activity against TNBC cells and improved cytotoxicity. One major advantage of analog 9 is that a pilot dose range finding study demonstrated that this analog elicited no signs of toxicity, whereas clofarabine was not well tolerated.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    clofarabine
    7ms
    Cross-Species Functional Genomic Screens Identify Novel Therapeutic Targets in Malignant Peripheral Nerve Sheath Tumors. (PubMed, Am J Pathol)
    Five druggable targets were selected for validation, with four of the five agents tested proving effective against human MPNST cells (the POLA1 inhibitor clofarabine, DNTT inhibitor cordycepin, BCL6 inhibitor 79-6 and LPAR1/3 inhibitor Ki16425). Clofarabine was especially effective, potently reducing cell numbers at low nanomolar concentrations and inducing a senescent phenotype, possibly via the p53/p21 pathway. These results demonstrate the utility of cross-species functional oncogenomics for the discovery of novel therapeutic targets relevant to human MPNSTs and suggest that clofarabine warrants further evaluation for its therapeutic potential.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • POLA1 (DNA Polymerase Alpha 1)
    |
    clofarabine • cordycepin (OVI-123)
    7ms
    Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children (clinicaltrials.gov)
    P2, N=20, Recruiting, West China Second University Hospital
    New P2 trial • Real-world evidence
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • clofarabine
    8ms
    A Multicenter Clinical Study of Clofarabine as Salvage Therapy in Children with Refractory/Relapsed Langerhans Cell Histiocytosis (ChiCTR2500102536)
    P4, N=66, Recruiting, Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University
    New P4 trial
    |
    clofarabine
    8ms
    Clofarabine Enhances the Transduction Efficiency of Recombinant AAV2 in the Retina. (PubMed, Invest Ophthalmol Vis Sci)
    Clofarabine safely enhances rAAV2 transduction efficiency in both ocular cell models and murine retinas. Its ability to synchronize cell cycles in dividing cells and reprogram transcriptional landscapes in postmitotic cells positions it as a promising adjunct for rAAV-based ocular gene therapy, potentially decreasing therapeutic vector doses and improving clinical outcomes.
    Journal
    |
    CCNE2 (Cyclin E2)
    |
    clofarabine
    8ms
    Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease (clinicaltrials.gov)
    P1/2, N=14, Not yet recruiting, Stanford University
    New P1/2 trial
    |
    Rituxan (rituximab) • prednisone • clofarabine • melphalan • Kepivance (palifermin)